Genomics of Acute Myeloid Leukemia

Recurring mutations found by sequencing an acute myeloid leukemia genome.

E. Mardis, L. Ding, D. Dooling, et al.. (2009). The New England journal of medicine. Cited 2,285 times. https://doi.org/10.1056/NEJMoa0903840

Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing

L. Ding, T. Ley, D. Larson, et al.. (2011). Nature. Cited 2,050 times. https://doi.org/10.1038/nature10738

The Origin and Evolution of Mutations in Acute Myeloid Leukemia

J. Welch, T. Ley, D. Link, et al.. (2012). Cell. Cited 1,557 times. https://doi.org/10.1016/j.cell.2012.06.023

DNA sequencing of a cytogenetically normal acute myeloid leukemia genome

T. Ley, E. Mardis, L. Ding, et al.. (2008). Nature. Cited 1,407 times. https://doi.org/10.1038/nature07485

Clonal architecture of secondary acute myeloid leukemia.

M. Walter, D. Shen, L. Ding, et al.. (2012). The New England journal of medicine. Cited 781 times. https://doi.org/10.1056/NEJMoa1106968

RECURRENT MUTATIONS IN THE U2AF1 SPLICING FACTOR IN MYELODYSPLASTIC SYNDROMES

T. Graubert, D. Shen, L. Ding, et al.. (2011). Nature genetics. Cited 580 times. https://doi.org/10.1038/ng.1031

The Role of TP53 Mutations in the Origin and Evolution of Therapy-Related AML

Terrence N Wong, G. Ramsingh, A. Young, et al.. (2014). Nature. Cited 547 times. https://doi.org/10.1038/nature13968

Functional heterogeneity of genetically defined subclones in acute myeloid leukemia.

J. Klco, D. Spencer, Christopher A. Miller, et al.. (2014). Cancer cell. Cited 379 times. https://doi.org/10.1016/j.ccr.2014.01.031

Immune Escape of Relapsed AML Cells after Allogeneic Transplantation

Matthew J. Christopher, A. Petti, M. Rettig, et al.. (2018). The New England Journal of Medicine. Cited 353 times. https://doi.org/10.1056/NEJMoa1808777

Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia.

J. Klco, Christopher A. Miller, M. Griffith, et al.. (2015). JAMA. Cited 322 times. https://doi.org/10.1001/jama.2015.9643

Clonal diversity of recurrently mutated genes in myelodysplastic syndromes

M. Walter, D. Shen, J. Shao, et al.. (2013). Leukemia. Cited 287 times. https://doi.org/10.1038/leu.2013.58

Use of whole-genome sequencing to diagnose a cryptic fusion oncogene.

J. Welch, P. Westervelt, L. Ding, et al.. (2011). JAMA. Cited 271 times. https://doi.org/10.1001/jama.2011.497

Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia.

J. Churpek, Khateriaa Pyrtel, K. Kanchi, et al.. (2015). Blood. Cited 233 times. https://doi.org/10.1182/blood-2015-04-641100

Optimizing cancer genome sequencing and analysis.

M. Griffith, Christopher A. Miller, O. Griffith, et al.. (2015). Cell systems. Cited 198 times. https://doi.org/10.7490/F1000RESEARCH.1110088.1

A general approach for detecting expressed mutations in AML cells using single cell RNA-sequencing

A. Petti, Stephen R. Williams, Christopher A. Miller, et al.. (2019). Nature Communications. Cited 183 times. https://doi.org/10.1038/s41467-019-11591-1

Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML.

D. Link, Laura G. Schuettpelz, D. Shen, et al.. (2011). JAMA. Cited 172 times. https://doi.org/10.1001/jama.2011.473

Clonal Architecture of Secondary Acute Myeloid Leukemia Defined by Single-Cell Sequencing

Andrew E. O. Hughes, V. Magrini, Ryan T. Demeter, et al.. (2014). PLoS Genetics. Cited 133 times. https://doi.org/10.1371/journal.pgen.1004462

U2AF1 Mutations Alter Sequence Specificity of pre-mRNA Binding and Splicing

Theresa Okeyo-Owuor, B. S. White, Rakesh Chatrikhi, et al.. (2014). Leukemia. Cited 123 times. https://doi.org/10.1038/leu.2014.303

Epigenomic analysis of the HOX gene loci reveals mechanisms that may control canonical expression patterns in AML and normal hematopoietic cells

D. Spencer, Margaret A. Young, T. Lamprecht, et al.. (2015). Leukemia. Cited 123 times. https://doi.org/10.1038/leu.2015.6

Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML.

Terrence N Wong, Christopher A. Miller, J. Klco, et al.. (2016). Blood. Cited 102 times. https://doi.org/10.1182/blood-2015-10-677021

Dynamic Changes in the Clonal Structure of MDS and AML in Response to Epigenetic Therapy

G. Uy, E. Duncavage, Gue Su Chang, et al.. (2016). Leukemia. Cited 96 times. https://doi.org/10.1038/leu.2016.282

Mutation Clearance after Transplantation for Myelodysplastic Syndrome

E. Duncavage, Meagan A. Jacoby, Gue Su Chang, et al.. (2018). The New England Journal of Medicine. Cited 68 times. https://doi.org/10.1056/NEJMoa1804714

Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant.

Meagan A. Jacoby, E. Duncavage, Gue Su Chang, et al.. (2018). JCI insight. Cited 53 times. https://doi.org/10.1172/jci.insight.98962

Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy.

E. Duncavage, G. Uy, A. Petti, et al.. (2017). Blood. Cited 24 times. https://doi.org/10.1182/blood-2016-10-745273

Comprehensive discovery of noncoding RNAs in acute myeloid leukemia cell transcriptomes.

Jin Zhang, M. Griffith, Christopher A. Miller, et al.. (2017). Experimental hematology. Cited 10 times. https://doi.org/10.1016/j.exphem.2017.07.008

Targeted Sequencing Informs the Evaluation of Normal Karyotype Cytopenic Patients for Low-Grade Myelodysplastic Syndrome

E. Duncavage, Jennifer O'Brien, Kiran R Vij, et al.. (2016). Leukemia. Cited 8 times. https://doi.org/10.1038/leu.2016.247